Treatment of Lymphangiomas With OK-432 (Picibanil) Sclerotherapy

Abstract

OK-432 should be efficacious in the treatment of lymphangiomas. Our study design is well structured to clearly define the role of this treatment agent.

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

“…Several drugs or chemicals have been used as agents for sclerotherapy of LM, including bleomycin, doxycycline, ethanol, and OK-432 (3,(19)(20)(21). Despite the complications by penetration into adjacent tissue, ethanol has been used as the strongest sclerosant for more definite results (10,22,23).…”

“…Recently, direct puncture sclerotherapy has been used as an initial treatment of choice and achieved more favorable results than surgical treatment (3). In a prospective survey using OK-432 (Picibanil…”

Uso de OK-432 em crianças com linfangioma

“…1 Microcystic lymphangioma (capillary or cavernous) exhibited a poorer response OK-432. [1][2][3]7,8,10 Even in the absence of a complete response, there was a significant volume reduction in two of the patients suffering from microcystic lymphangioma (50-60%). This could facilitate surgery in the case it becomes necessary.…”

“…There are description of the lesions recurring in up to 27% of cases. [1][2][3][4][5][6][7][8] The limitations of surgical solutions have awoken interest in other therapeutic methods, such as the administration of sclerosing agents such as bleomycin and hypotonic salt solutions that provoke an inflammation of the vascular endothelium leading to total or partial remission of the lymphangioma. [1][2][3][4][5][6]8 These substances can be diffused, via the walls of the cyst, to adjacent tissues, which can provoke an inflammatory reaction and scar retraction, which may extend beyond the limits of the original lymphangioma, with unsatisfactory aesthetic results and increased difficulties for future surgery.…”

“…4 Despite the limitations that make sclerosing agents unsatisfactory for the treatment of lymphangioma, a new agent, OK-432, produced by lyophilization of a culture of low virulence Su strains of group A Streptococcus pyogenes treated with penicillin G potassium, has been used with good results. [1][2][3][5][6][7][8][9][10] It has been approved for use by the Japanese Health Ministry for use as a biological response modifier and was initially used in clinical trials for neoplasms of the head and neck. 11 Since 1987, OK-432 has been used for lymphangioma treatment in counties such as Japan.…”